Back to News
Market Impact: 0.3

Stocks making the biggest moves midday: Netflix, Xenon Pharmaceuticals, Coinbase, Sandisk, SpaceX & more

Source: CNBC

+10
Market Technicals & FlowsCrypto & Digital AssetsHealthcare & BiotechCorporate Guidance & OutlookAnalyst InsightsTechnology & Innovation
Stocks making the biggest moves midday: Netflix, Xenon Pharmaceuticals, Coinbase, Sandisk, SpaceX & more

Midday trading was mixed, led by Xenon Pharmaceuticals' 30% plunge after it paused enrollment in depression studies due to neuropsychiatric side effects, while Steel Dynamics and Nucor fell more than 4% and 6%, respectively, on weak Q3 guidance. Crypto-linked stocks rallied as bitcoin rose nearly 6% above $80,000, lifting Coinbase 11%, Robinhood 8% and Strategy 12%. Semiconductor shares also advanced, with Lam Research up 5%, Applied Materials up 4% and the SMH ETF up about 0.6%, while Netflix fell nearly 5% following a Wells Fargo downgrade.

Analysis

The steel guidance reset is more consequential for STLD and NUE than a single-quarter miss: it implies that incremental volume is being absorbed at lower spreads, while scrap/input economics are no longer providing the offset investors expected. The second-order read-through is negative for SCHN and other ferrous-scrap-exposed names if mill utilization weakens, but potentially constructive for steel-consuming manufacturers only if lower coil pricing persists into 1Q. Over the next 1-3 months, the key falsifier is a recovery in sheet pricing and order books; absent that, consensus 2027 EBITDA estimates for the mini-mills remain vulnerable.

Crypto equities are offering leveraged beta rather than clean exposure: COIN benefits from both spot volumes and higher transaction take-rate opportunity, while HOOD requires sustained retail engagement to convert price volatility into earnings. MSTR adds balance-sheet convexity but also carries the greatest downside in a 10-15% bitcoin retracement because its premium to underlying holdings can compress simultaneously. The near-term move is flow-driven and can persist for days, but a 1-3 month thesis requires confirmation in exchange volumes, stablecoin issuance, and net retail asset inflows rather than bitcoin price alone.

The semiconductor advance appears broad enough to be technical rather than a new fundamental information event. AMAT and LRCX remain the higher-quality ways to express wafer-fab equipment demand, but memory-linked SNDK and STX have greater downside if pricing momentum stalls after inventory replenishment; do not chase a fourth consecutive up day without evidence of upward revisions. In contrast, the SpaceX schedule shift is not itself a material operating read-through for RKLB or LUNR; their selloff may create an entry opportunity only if contract awards, launch cadence, and cash burn remain intact. XENE's enrollment pause changes the probability-weighted value of its psychiatric pipeline, and the stock should be treated as uninvestable until the safety signal, protocol remediation, and regulator feedback are disclosed.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

-0.05

Ticker Sentiment

AMAT0.45
AVGO0.32
COIN0.62
HOOD0.52
LRCX0.50
LUNR-0.42
MSTR0.65
MTSI0.58
NFLX-0.72
NUE-0.65
RKLB-0.42
SNDK0.60
SPCX-0.18
STLD-0.58
STX0.42
XENE-0.92

Key Decisions for Investors

  • Initiate a 1-3 month pair: short STLD / long XLI, sized modestly. This isolates mill-spread and estimate-cut risk from a broad cyclical rebound; cover if STLD restores segment guidance or domestic hot-rolled coil pricing rises materially for four consecutive weeks.
  • Prefer long COIN over MSTR for tactical crypto exposure over the next 2-6 weeks; use a 12-15% bitcoin drawdown or a deterioration in reported trading-volume trends as a stop condition. COIN has more direct operating upside from elevated volatility, whereas MSTR is more exposed to NAV-premium compression.
  • Do not add to AMAT or LRCX after the current momentum move; place an alert for post-earnings estimate revisions or a 5-8% pullback. A long AMAT/LRCX basket is warranted only if foundry and memory capex commentary confirms 2027 tool-demand durability.
  • Avoid XENE pending a quantified safety update and trial-enrollment restart. A restart alone is insufficient; re-evaluate only when discontinuation rates, adverse-event severity, and the resulting development timeline are disclosed.
  • Watch RKLB and LUNR for idiosyncratic catalysts rather than trade the shared launch-delay reaction. Consider a 3-6 month long RKLB only on confirmation that launch cadence and backlog conversion remain unaffected; a revised launch schedule or higher cash-burn outlook would invalidate the setup.

More News

From AllMind Research

Browse all research